TABLE 2.
Univariable Cox Regression Analysis for Association with PSA PFS and OS
| Variable | OS | PSA PFS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Increase in PSMA TTV (L) | 6.2 | 2.0–19.2 | 0.002 | 2.9 | 1.4–6.1 | 0.01 |
| Increase in PSMA SUVmax at trial exit | 1.9 | 0.2–14.4 | 0.56 | 1.3 | 0.3–5.6 | 0.71 |
| Increase in 18F-FDG TTV (L) | 2.7 | 1.1–6.2 | 0.02 | 3.1 | 1.4–6.8 | 0.005 |
| Increase in 18F-FDG SUVmax at trial exit | 3.0 | 1.2–7.3 | 0.02 | 3.0 | 1.4–6.4 | 0.01 |
| PSA progression at trial exit | 5.8 | 2.1–16.1 | <0.001 | 5.0 | 2.3–10.7 | <0.001 |
| Radiographic progression at trial exit | 5.4 | 1.8–16 | 0.003 | 4.4 | 1.6–12 | 0.004 |